Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Brain acetylcholinesterase activity was determined in healthy controls and in patients with mild cognitive impairment and early Alzheimer's disease. METHODS: A specific acetylcholinesterase tracer, [methyl-(11)C]N-methyl-piperidyl-4-acetate ([(11)C]MP4A), and a three dimensional PET system with magnetic resonance coregistration were used for imaging. RESULTS: There was a significant difference in the acetylcholinesterase activity in the hippocampus between the groups (p = 0.03), the mean (SD) acetylcholinesterase activity (k(3) values, min(-1)) being 0.114 (0.036) in controls, 0.098 (0.023) in mild cognitive impairment, and 0.085 (0.022) in Alzheimer's disease. The mini-mental state examination score showed no significant relation with acetylcholinesterase activity in any brain area in the combined mild cognitive impairment/Alzheimer group. CONCLUSIONS: Hippocampal acetylcholinesterase activity is only slightly reduced in mild cognitive impairment and early Alzheimer's disease and so the value of in vivo acetylcholinesterase measurements in detecting the early Alzheimer process is limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686
Hippocampal formation glucose metabolism and volume losses in MCI and AD
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00230-5 · Cited by 548
Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K., & Irie, T. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09124-6 · Cited by 259
Cited by
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline
Ballinger, E. C., Ananth, M., Talmage, D. A., & Role, L. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.006 · Cited by 730
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Bohnen, N. I., Kaufer, D. I., Ivanco, L. S., Lopresti, B., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 551
Advances in the early detection of Alzheimer's disease
Nestor, P. J., Scheltens, P., & Hodges, J. R. (2004) · Nature Medicine · doi:10.1038/nrn1433 · Cited by 463
The use of PET in Alzheimer disease
Nordberg, A., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 449
Self-citationManagement of behavioral problems in Alzheimer's disease
Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., & Lyketsos, C. (2010) · International Psychogeriatrics · doi:10.1017/s1041610209991505 · Cited by 361
Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease
Chetelat, G., Desgranges, B., Landeau, B., Mezenge, F., Poline, J. B., de la Sayette, V., Viader, F., Eustache, F., & Baron, J.-C. (2007) · Brain · doi:10.1093/brain/awm288 · Cited by 339
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Li, C., Zhao, R., Gao, K., Wei, Z., Yaoyao Yin, M., Ting Lau, L., Chui, D., & Cheung Hoi Yu, A. (2011) · Current Alzheimer Research · doi:10.2174/156720511794604543 · Cited by 289
Positron emission tomography imaging in dementia
HERHOLZ, K., CARTER, S. F., & JONES, M. (2007) · The British Journal of Radiology · doi:10.1259/bjr/97295129 · Cited by 287
Mild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
Aghourian, M., Legault-Denis, C., Soucy, J.-P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., & Bédard, M.-A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.183 · Cited by 220
The Neurotrophins and Their Role in Alzheimers Disease
J. Allen, S., J. Watson, J., & Dawbarn, D. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376190 · Cited by 177
“In addition cortical acetylcholinesterase activity has been shown to be reduced [11,12].”
BackgroundSalivary biomarkers for the diagnosis and monitoring of neurological diseases
Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D. M., & Said Sadier, N. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.03.004 · Cited by 170
“Assessment of AChE catalytic activity in ADpatientsbyconventionalmethodssuchaspositronemission tomography showeda significant decrease in this activity in the affected brain regions [70,71].”
BackgroundEffect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., Neumaier, B., Fink, G. R., & Kukolja, J. (2018) · Brain · doi:10.1093/brain/awx356 · Cited by 77
“…show similar alterations to AChE: their levels are decreased in PET studies of MCI and early dementia due to Alzheimer’s disease, albeit to a lesser extent than in later stages (Kuhl et al., 1996; Nordberg, 2001; Rinne et al., 2003; Mazère et al., 2008; Haense et al., 2012; Marcone et al., 2012).”
BackgroundMarcone, A., Garibotto, V., Moresco, R. M., Florea, I., Panzacchi, A., Carpinelli, A., Virta, J. R., Tettamanti, M., Borroni, B., Padovani, A., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111748 · Cited by 51
Self-citationPeng, Y., Tao, H., Wang, S., Xiao, J., Wang, Y., & Su, H. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104463 · Cited by 31
Metadata
- Authors
- Rinne, J. O.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2003-01-01
- Volume
- 74
- Issue
- 1
- Pages
- 113-115
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2122172872
- Cited by
- 153
- References
- 6
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.